Meeting
2021 ASCO Quality Care Symposium
Real-world utilization and costs with biosimilar and reference filgrastim in patients with breast cancer receiving myelosuppressive chemotherapy in a community oncology setting from 2015 to 2017.
Authors
Robert M. Rifkin
US Oncology Research Inc. and Rocky Mountain Cancer Centers, Denver, CO
Robert M. Rifkin, Lisa Herms, Chuck Wentworth, Anupama Vasudevan, Kimberley Campbell, Edward C. Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience
Track
Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 57)
DOI
10.1200/JCO.2020.39.28_suppl.57
Abstract #
57
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy.
First Author: Andriy Krendyukov
Poster
2023 ASCO Quality Care Symposium
Growth factor use in patients with breast cancer treated with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen: Cost implications in a safety-net system.
First Author: Sarah Kashanian
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).
First Author: Douglas W. Blayney
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw